Fc-fusion proteins are bioengineered polypeptides that join the crystallizable fragment (Fc) domain of an antibody with another biologically active protein domain or peptide to generate a molecule with unique structure–function properties and significant therapeutic potential. The gamma immunoglobulin (IgG) isotype is often used as the basis for generating Fc-fusion proteins
The global market for Therapeutic Fc Fusion Protein is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Therapeutic Fc Fusion Protein market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Therapeutic Fc Fusion Protein market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Therapeutic Fc Fusion Protein market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Therapeutic Fc Fusion Protein market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Therapeutic Fc Fusion Protein players cover Sanofi, Bristol-Myers Squibb, Regeneron, Bayer and Amgen, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Therapeutic Fc Fusion Protein market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Therapeutic Fc Fusion Protein market, with both quantitative and qualitative data, to help readers understand how the Therapeutic Fc Fusion Protein market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Therapeutic Fc Fusion Protein market and forecasts the market size by Type (Brands Drugs and Biosimilar Drugs,), by Application (Autoimmune Disease, Eye Diseases, Diabetes and Hemophilia), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Brands Drugs
Biosimilar Drugs
Segmentation by application
Autoimmune Disease
Eye Diseases
Diabetes
Hemophilia
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Sanofi
Bristol-Myers Squibb
Regeneron
Bayer
Amgen
Pfizer
Eli Lilly and Company
Sobi
Kanghong Pharma
3SBIO
Celgen Biopharma
Chapter Introduction
Chapter 1: Scope of Therapeutic Fc Fusion Protein, Research Methodology, etc.
Chapter 2: Executive Summary, global Therapeutic Fc Fusion Protein market size and CAGR, Therapeutic Fc Fusion Protein market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Therapeutic Fc Fusion Protein revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Therapeutic Fc Fusion Protein revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Therapeutic Fc Fusion Protein market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, Bristol-Myers Squibb, Regeneron, Bayer, Amgen, Pfizer, Eli Lilly and Company, Sobi and Kanghong Pharma, etc.
Chapter 14: Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Therapeutic Fc Fusion Protein. Industry analysis & Market Report on Therapeutic Fc Fusion Protein is a syndicated market report, published as Global Therapeutic Fc Fusion Protein Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Therapeutic Fc Fusion Protein market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.